Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

AURA Phase 2 clinical trial designed to evaluate the safety and efficacy of AP02 compared to placebo in patients with idiopathic pulmonary fibrosis (IPF) BOSTON, March 23, 2026 (GLOBE NEWSWIRE)-- ...

BOSTON, March 23, 2026 (GLOBE NEWSWIRE)-- Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

BOSTON, March 25, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis. A new systematic review and meta-analysis suggests ...

Thirteen observational studies comparing hormonal contraception use among women with idiopathic intracranial hypertension (IIH; 5351 women) and controls without IIH (669,260 women) were included.

Please provide your email address to receive an email when new articles are posted on . The meta-analysis featured 13 observational studies. A link between hormonal contraception and idiopathic ...

Metabolic disease is reshaping care delivery and costs, with experts at the Academy of Managed Care Pharmacy (AMCP) 2026 ...